News
Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...
In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...
It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...
That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London ...
AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...
With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...
President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...
AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...
The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well as for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results